A Study of ALKS 4230 With Pembrolizumab in Head and Neck Cancer

Condition:   Non-cutaneous Squamous Cell Carcinoma of Head and Neck Interventions:   Drug: ALKS 4230;   Drug: Pembrolizumab Sponsors:   Alkermes, Inc.;   Immune Oncology Network Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials